SCHEMBL3564713

SCHEMBL3564713

Cn1ccc2cc(-c3cnc(N)c4c(-c5ccc(N)cc5)csc34)ccc21

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 7/20 0.49
EPHB4 P54760 5/20 0.49
KDR P35968 4/20 0.49
LRRK2 Q5S007 1/20 0.47
RIPK1 Q13546 1/20 0.45
RIPK3 Q9Y572 1/20 0.45
AURKB Q96GD4 3/20 0.44
AURKA O14965 2/20 0.44
ROCK2 O75116 2/20 0.44
MAP4K4 O95819 2/20 0.44
ABL1 P00519 2/20 0.44
INSR P06213 2/20 0.44
FYN P06241 2/20 0.44
CSF1R P07333 2/20 0.44
LYN P07948 2/20 0.44
KIT P10721 2/20 0.44
FGFR1 P11362 2/20 0.44
FLT1 P17948 2/20 0.44
FGFR3 P22607 2/20 0.44
AXL P30530 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3528912 0.81 BTK (0.61) BTKEPHB4KDRAURKBAURKA
SCHEMBL3584444 0.80 KDR (0.74) BTKKDRLRRK2AURKBAURKA
SCHEMBL3573037 0.79 KDR (0.72) BTKKDRLRRK2AURKBAURKA
SCHEMBL27661148 0.79 KDR (0.49) BTKEPHB4KDRLRRK2AURKB
SCHEMBL27661270 0.78 EPHB4 (0.44) BTKEPHB4KDRLRRK2AURKB
SCHEMBL3578809 0.77 BTK (0.55) BTKEPHB4KDRAURKBAURKA
SCHEMBL3566621 0.76 KDR (0.71) BTKEPHB4KDRRIPK1RIPK3
SCHEMBL3532992 0.76 KDR (0.71) BTKEPHB4KDRRIPK1RIPK3
SCHEMBL3565790 0.76 BTK (0.67) BTKEPHB4KDRLRRK2AURKB
SCHEMBL3529981 0.76 BTK (0.70) BTKEPHB4KDRAURKBAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103087078-A Thienopyridine and furopyridine kinase inhibitors ABBOTT LAB 2013-05-08 CN disclosed
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
CN-1856498-A Thienopyridine and furopyridine kinase inhibitors ABBOTT LAB (US) 2006-11-01 CN disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK BTK 103/4885EPHB4 896/4885KDR 494/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK BTK 103/4885EPHB4 896/4885KDR 494/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK BTK 103/4885EPHB4 896/4885KDR 494/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK BTK 103/4885EPHB4 896/4885KDR 494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.